Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
86
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers

Dongseong Shin1 Department of Pharmacology, Gachon University College of Medicine, Incheon, Korea;2 Clinical Trials Center, Gachon University Gil Medical Center, Incheon, Korea;3 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea
,
Sang-In Park4 Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Korea;5 East-West Medical Research Institute, Kyung Hee University, Seoul, Korea
,
Hong-Sub Lee6 Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
,
Kyung-Mi An6 Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
,
Juyoung Jung6 Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
,
MyongJae Lee6 Research Laboratories ILDONG Pharmaceutical Co. Ltd, Hwaseong, Korea
&
Kyung-Sang Yu3 Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, KoreaCorrespondence[email protected]
 show all
Pages 2483-2490 | Published online: 24 Jul 2019

References

  • Giglione C, Pierre M, Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol. 2000;36(6):1197–1205.10931273
  • Lee HY, An KM, Jung J, et al. Identification of novel aminopiperidine derivatives for antibacterial activity against gram-positive bacteria. Bioorg Med Chem Lett. 2016;26(13):3148–3152. doi:10.1016/j.bmcl.2016.04.08627173797
  • Lofland D, Difuntorum S, Waller A, et al. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother. 2004;53(4):664–668. doi:10.1093/jac/dkh12914973152
  • Johnson KW, Lofland D, Moser HE. PDF inhibitors: an emerging class of antibacterial drugs. Curr Drug Targets Infect Disord. 2005;5(1):39–52.15777197
  • Gross M, Clements J, Beckett RP, et al. Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. J Antimicrob Chemother. 2004;53(3):487–493. doi:10.1093/jac/dkh10814963065
  • Fu H, Dahlgren C, Bylund J. Subinhibitory concentrations of the deformylase inhibitor actinonin increase bacterial release of neutrophil-activating peptides: a new approach to antimicrobial chemotherapy. Antimicrob Agents Chemother. 2003;47(8):2545–2550. doi:10.1128/aac.47.8.2545-2550.200312878517
  • Lee M, Kim D, Shin J, et al. Quantification of IDP-73152, a novel antibiotic, in plasma from mice, rats and humans using an ultra-high performance liquid chromatography/tandem mass spectrometry method for use in pharmacokinetic studies. J Pharm Biomed Anal. 2017;145:364–371. doi:10.1016/j.jpba.2017.06.06628715789
  • Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother. 2013;57(5):2005–2009. doi:10.1128/AAC.01779-1223403431
  • Ramanathan-Girish S, McColm J, Clements JM, et al. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother. 2004;48(12):4835–4842. doi:10.1128/AAC.48.12.4835-4842.200415561864
  • Rolan P, Sun H, Macleod C, Bracken K, Evans TG. Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor. Clin Pharmacol Ther. 2011;90(2):256–262. doi:10.1038/clpt.2011.10121716277
  • Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox MH. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959–1974. doi:10.2147/IDR.S17236630464538
  • Mamelli L, Petit S, Chevalier J, et al. New antibiotic molecules: bypassing the membrane barrier of gram negative bacteria increases the activity of peptide deformylase inhibitors. PLoS One. 2009;4(7):e6443. doi:10.1371/journal.pone.000644319649280
  • Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3(5):241–253. doi:10.1177/204209861245428325083239

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.